CKLSF'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -2.37 Med: 1.84 Max: 4.25
Current: -2.37
During the past 13 years, CK Life Sciences International Holdings's highest Return-on-Tangible-Asset was 4.25%. The lowest was -2.37%. And the median was 1.84%.
CKLSF's Return-on-Tangible-Asset is ranked better than 78.27% of 1413
companies
in the Biotechnology industry
Industry Median: -35.75
vs CKLSF: -2.37
CK Life Sciences International Holdings (OTCPK:CKLSF) Return-on-Tangible-Asset Explanation
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
CK Life Sciences International Holdings Return-on-Tangible-Asset Related Terms
CK Life Sciences International Holdings Return-on-Tangible-Asset Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CK Life Sciences International Holdings Return-on-Tangible-Asset Chart
CK Life Sciences International Holdings Annual Data
CKLSF vs VRTX, REGN, ALNY: Return-on-Tangible-Asset Comparison
For the Biotechnology subindustry, CK Life Sciences International Holdings's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CK Life Sciences International Holdings Return-on-Tangible-Asset vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, CK Life Sciences International Holdings's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where CK Life Sciences International Holdings's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is two times the semi-annual (Dec. 2025) net income data.
What does a Return-on-Tangible-Asset of -0.89% mean?
CK Life Sciences International Holdings (CKLSF) has a Return-on-Tangible-Asset of -0.89% as of Dec. 2025. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on CK Life Sciences International Holdings and its competitors. According to the industry distribution chart, CK Life Sciences International Holdings ranks #307 out of 1413 companies in the Biotechnology industry, placing it in the top 21.7%.
Is CK Life Sciences International Holdings' Return-on-Tangible-Asset too high?
CK Life Sciences International Holdings' current Return-on-Tangible-Asset is -0.89%. Based on the distribution chart, CK Life Sciences International Holdings ranks #307 out of 1413 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, CK Life Sciences International Holdings has a GF Score™ of 39/100, reflecting its overall financial health beyond just this single metric.
How does CK Life Sciences International Holdings' Return-on-Tangible-Asset compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, CK Life Sciences International Holdings ranks #307 out of 1413 companies for Return-on-Tangible-Asset. This places CK Life Sciences International Holdings in the top 22% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Biotechnology company?
A good Return-on-Tangible-Asset depends on the Biotechnology industry context. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on CK Life Sciences International Holdings and its competitors. CK Life Sciences International Holdings's current Return-on-Tangible-Asset is -0.89%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CK Life Sciences International Holdings stock overvalued right now?
CK Life Sciences International Holdings (CKLSF) has a current Return-on-Tangible-Asset of -0.89%. The stock's GF Value™ is $0.11, compared to a current price of $0.09 — trading 18.2% below its estimated fair value. The current Return-on-Tangible-Asset is -0.89%. CK Life Sciences International Holdings' overall GF Score™ is 39/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For CK Life Sciences International Holdings (CKLSF), the current Return-on-Tangible-Asset is -0.89% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is CK Life Sciences International Holdings (CKLSF) Overvalued in 2026?
Based on GuruFocus' analysis, CK Life Sciences International Holdings stock appears to be undervalued.
The current stock price of $0.09 is trading 18.2% below its estimated GF Value™ of $0.11.
Key valuation signals for CKLSF:
Return-on-Tangible-Asset: -0.89%
GF Value™: $0.11 vs. price of $0.09 (18.2% below fair value)
No single metric tells the full story. See the CKLSF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
CK Life Sciences International Holdings Business Description
CK Life Sciences International Holdings Inc is an international life sciences company. It is engaged in research and development, manufacturing, commercialization, marketing and selling of health and agriculture-related products, as well as investment in a portfolio of vineyards, and various financial and investment products. Its pipeline includes Seviprotimut-L, TTX-MC138, Seviprotimut-L + TTX-MC138, TTX-RIGA, Halneuron, among others. Its segments include Agriculture-related, Nutraceutical, and Pharmaceuticals & Diagnostics R&D with the majority of the revenue deriving from Nutraceutical segment. Geographically it operates in Asia Pacific that derives the majority of the revenue and North America.
39GF Score
Get the complete analysis for CKLSF
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CKLSF has been successfully added to your 
